Peimisine ameliorates diabetic nephropathy by attenuating inflammation and ferroptosis through inhibition of the JAK/STAT pathway.
文献摘要
This study aimed to investigate the effect of peimisine on diabetic nephropathy (DN) and explore its potential mechanisms in a mouse model of high-fat diet and streptozocin-induced DN and cell model of high glucose (HG)-treated MPC5 cells. The beneficial effects of peimisine in DN mice were analyzed via determining body weight, fasting blood glucose, plasma total cholesterol, plasma triglyceride, serum creatinine, blood urea nitrogen, pathological changes, oxidative stress markers, inflammatory cytokines, and ferroptosis-related indicators. Furthermore, CCK-8 assay, flow cytometry, inflammatory cytokines, mitochondrial membrane potential (MMP) detection, DCFH-DA probe, BODIPY 581/591 C11 probe, oxidative stress markers, and ferroptosis-related indicators were conducted to measure the beneficial effects of peimisine on HG-treated MPC5 cells. qRT-PCR and western blotting were employed for determining Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway-associated genes expression. The potential mechanism was further investigated through rescue experiments using RO8191 (a JAK activator). We discovered that peimisine could ameliorate metabolic dysfunction, and the impairment of renal function and structure in DN mice. Moreover, peimisine could ameliorate inflammation and ferroptosis in DN mice. Similarly, peimisine was also demonstrated to ameliorate inflammation and ferroptosis in HG-treated MPC5 cells. Mechanistically, peimisine could inhibit the JAK/STAT pathway in vitro and in vivo. The inhibitory effects of peimisine on inflammation and ferroptosis in HG-treated MPC5 cells were reversed by RO8191. Our findings demonstrated that peimisine could ameliorate DN by attenuating inflammatory responses and ferroptosis through inhibition of the JAK/STAT signaling.